Welcome to our dedicated page for Atai Beckley news (Ticker: ATAI), a resource for investors and traders seeking the latest updates and insights on Atai Beckley stock.
AtaiBeckley Inc. develops clinical-stage biotechnology programs for mental health conditions, with news centered on investigational therapies for treatment-resistant depression and social anxiety disorder. Recurring updates cover BPL-003, a mebufotenin benzoate nasal spray with FDA Breakthrough Therapy Designation for treatment-resistant depression; VLS-01, a DMT buccal film; and EMP-01, an oral R-MDMA program for social anxiety disorder.
Company announcements also address peer-reviewed clinical data, FDA interactions, patient-participant research practices, financial results, R&D spending, acquisition-related integration with Beckley Psytech, equity index inclusion, and capital runway disclosures. The news flow reflects a clinical-stage issuer whose operating updates are tied primarily to psychiatry-focused development programs, regulatory engagement, and financing capacity.
AtaiBeckley (NASDAQ: ATAI) said it remains on track to start two parallel Phase 3 studies of BPL-003 in Q2 2026 after a successful End-of-Phase 2 meeting with the FDA. BPL-003 holds Breakthrough Therapy Designation and showed rapid Day 2 antidepressant effects and durable improvements through eight weeks in Phase 2b.
The company reaffirmed cash runway into early 2029, outlined a scalable commercial model aligned with interventional psychiatry workflows, noted positive Phase 2a results for EMP-01, and expects VLS-01 Phase 2 topline in H2 2026.
AtaiBeckley (NASDAQ: ATAI) reported Q4 and full-year 2025 results and clinical updates on March 6, 2026. Key clinical milestones include a successful FDA End-of-Phase 2 meeting for BPL-003 and Phase 3 initiation targeted for Q2 2026, VLS-01 Phase 2 topline readout expected in H2 2026, and positive Phase 2a EMP-01 SAD results. Financially, cash and short-term securities totaled $220.7M at year-end and management expects runway into early 2029. The company completed a strategic combination and U.S. redomiciliation in late 2025.
AtaiBeckley (NASDAQ: ATAI) announced a successful End-of-Phase 2 meeting with the FDA for BPL-003, its intranasal mebufotenin benzoate for treatment-resistant depression. The FDA indicated support for a dual pivotal Phase 3 program and provided feedback on the safety database.
The company expects Phase 3 initiation on track for Q2 2026, notes BPL-003 has Breakthrough Therapy designation (Oct 2025), and will host a Virtual Investor Day on March 6, 2026 to detail the Phase 3 strategy.
AtaiBeckley (NASDAQ: ATAI) reported positive topline results from a Phase 2a trial of EMP-01 (oral R-MDMA) in adults with Social Anxiety Disorder on February 26, 2026. The study met its primary safety objective with no serious adverse events and high retention.
EMP-01 showed a placebo-adjusted LSAS reduction of 11.85 points at Day 43 (Hedges’ g=0.45; p=0.036 one-tailed), 49% CGI‑I responders vs. 15% placebo (NNT 2.95). Seventy-one patients enrolled across seven UK sites; detailed analyses will appear at scientific venues.
AtaiBeckley (NASDAQ: ATAI) will host a Virtual Investor Day on Friday, March 6, 2026, from 9:00 a.m. to 12:00 p.m. ET. The event will include presentations and live Q&A with the company’s executive leadership and external key opinion leaders.
Investors, analysts, and media may register for the live webcast; a replay will be posted afterward on the company’s investor website under Events.
AtaiBeckley (NASDAQ: ATAI) appointed Michael Faerm as Chief Financial Officer effective March 9, 2026. Faerm brings more than 25 years of finance, equity research and banking experience and will lead financial strategy, capital markets and operations. Anne Johnson will transition to Chief Accounting Officer to preserve continuity. The company noted BPL-003 is advancing toward Phase 3 as its clinical programs progress.
AtaiBeckley (NASDAQ: ATAI) said its CEO Srinivas Rao, M.D., Ph.D., and VP of Investor Relations Jason Awe, Ph.D., will attend investor conferences in March 2026 with fireside chats and one-on-one meetings.
Events: TD Cowen (Boston) on March 4 with a fireside chat 11:50am–12:20pm EST; Jefferies Biotech on March 10 (one-on-ones) in Miami; Leerink (Miami) on March 11 with a fireside chat 8:00am–8:30am EST. Live webcasts of the fireside chats will be available on the company's investor site and archived for at least 30 days.
AtaiBeckley (NASDAQ: ATAI) presented new clinical and preclinical data at the 64th Annual ACNP Meeting (Jan 12–15, 2026) in Nassau, Bahamas. A Phase 2b double-blind study of intranasal BPL-003 (mebufotenin benzoate) showed that a single 8 mg or 12 mg dose produced a significant, rapid, and sustained antidepressant effect versus a 0.3 mg sub-perceptual control at all timepoints, with both active doses reported as well-tolerated. The BPL-003 poster was selected for the Hot Topics Session. A separate preclinical poster on 5-MeO-DMT reported pharmacology, pharmacokinetics, and potential neuroplasticity-relevant effects supporting further investigation. The company said these results support moving toward Phase 3 evaluation for BPL-003.
AtaiBeckley (NASDAQ: ATAI) provided a 2026 outlook ahead of the J.P. Morgan Healthcare Conference and highlighted clinical progress, corporate changes, and upcoming milestones.
Key clinical updates: positive Phase 2b topline results for BPL-003 (mebufotenin benzoate) in TRD with single-dose durable effects; OLE data supporting a 12 mg repeat dose; Phase 3 guidance expected in Q1’26 with potential initiation in Q2’26 pending an FDA End-of-Phase 2 meeting. Additional 2026 catalysts include H2’26 topline readout for VLS-01 and Q1’26 topline data for EMP-01. Corporate: redomiciled to the U.S., added to the NASDAQ biotech index, and expects funding into 2029.
AtaiBeckley (NASDAQ: ATAI) completed the redomiciliation of its parent from a Netherlands company to a Delaware corporation, effective after market close on Dec 30, 2025. All issued ordinary shares were exchanged on a one-for-one basis for newly issued common stock of AtaiBeckley Inc.
The redomiciliation was approved by approximately 99% of votes cast at the extraordinary general meeting on Nov 4, 2025. The company said it expects cost savings, simplified corporate structure, alignment with its U.S. listing and shareholder base, streamlined reporting and reduced administrative burden. Common stock will continue trading on NASDAQ under the symbol ATAI. For further details, see the company filings with the SEC.